GALT

Over the past six months, Galectin Therapeutics' stock price has been impacted by several events. In December 2025, the stock plummeted after the company received written feedback from the FDA regarding its belapectin development program, leading to a follow-up Type C meeting, however, the company announced a new $10 million unsecured, convertible line of credit from its chairman. In March 2026, the company reported its 2025 financial results and provided a business update, highlighting progress on belapectin for MASH cirrhosis and portal hypertension, noting a decrease in R&D expenses and an improved net loss. In February 2026, Galectin Therapeutics hosted a virtual Key Opinion Leader (KOL) event to discuss the belapectin development program for MASH cirrhosis and portal hypertension. In November 2025, the company reported financial results for the quarter ended September 30, 2025, and provided a business update on belapectin from the NAVIGATE trial.